Effects of synthetic cathinones contained in “bath salts” on motor behavior and a functional observational battery in mice

ACMD (Advisory Council on the Misuse of Drugs). Consideration of the cathinones; 2010.

al-Meshal, 1991, The toxicity of Catha edulis (khat) in mice, J Subst Abuse, 3, 107, 10.1016/S0899-3289(05)80011-2

American Association of Poison Control Centers. Bath salts data, Updated January 5, 2012; 2012.

Angoa-Pérez, 2012, Mephedrone, an abused psychoactive component of “bath salts” and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum, J Neurochem, 120, 1097, 10.1111/j.1471-4159.2011.07632.x

Antonowicz, 2011, Paranoid psychosis induced by consumption of methylenedioxypyrovalerone: two cases, Gen Hosp Psychiatry, 33, e5

Banjaw, 2003, Anticataleptic activity of cathinone and MDMA (Ecstasy) upon acute and subchronic administration in rat, Synapse, 49, 232, 10.1002/syn.10236

Banjaw, 2005, Clozapine attenuates the locomotor sensitisation and the prepulse inhibition deficit induced by a repeated oral administration of Catha edulis extract and cathinone in rats, Behav Brain Res, 160, 365, 10.1016/j.bbr.2005.01.002

Banjaw, 2006, Repeated Catha edulis oral administration enhances the baseline aggressive behavior in isolated rats, J Neural Transm, 113, 543, 10.1007/s00702-005-0356-7

Baumann, 2012, The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue, Neuropsychopharmacology, 37, 1192, 10.1038/npp.2011.304

Berardelli, 1980, Behavioral and EEG effects induced by an amphetamine like substance (cathinone) in rats, Pharmacol Res Commun, 12, 959, 10.1016/S0031-6989(80)80163-9

Calabrese, 2008, Addiction and dose response: the psychomotor stimulant theory of addiction reveals that hormetic dose responses are dominant, Crit Rev Toxicol, 387, 599, 10.1080/10408440802026315

Camilleri, 2010, Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluormethamphetamine, α-phthalimidopropiophenone and nethylcathinone, Forens Sci Int, 197, 59, 10.1016/j.forsciint.2009.12.048

CDC (Center for Disease Control), 2011, Emergency Department visits after use of a drug sold as “Bath Salts”, Morb Mortal Wkly Rep, 60, 624

Cozzi, 1999, Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines, Eur J Pharmacol, 381, 63, 10.1016/S0014-2999(99)00538-5

DEA (Drug Enforcement Agency). Synthetic cathinones – DEA request for information posted 3/31/11; 2011 [retrieved 28.07.11].

Eastwood, 2010, Legal eye, Drugs and Alcohol Today, 10, 6, 10.5042/daat.2010.0720

EMCDDA (European Monitoring Centre for Drugs and Drug Addiction). EMCDDA and Europol step up information collection on mephedrone; 2010.

Fischman, 1989, Relationship between self-reported drug effects and their reinforcing effects: studies with stimulant drugs, NIDA Res Monogr, 92, 211

Fleckenstein, 2000, Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity, Eur J Pharmacol., 406, 1, 10.1016/S0014-2999(00)00639-7

Forster, 1999, Estimating age-related changes in psychomotor function: influence of practice and of level of caloric intake in different genotypes, Neurobiol Aging, 20, 167, 10.1016/S0197-4580(99)00041-X

Frith, 1987, Toxicity of methylenedioxymethamphetamine (MDMA) in the dog and the rat, Fundam Appl Toxicol, 9, 110, 10.1016/0272-0590(87)90158-8

Gibbons, 2010, An analysis of the ‘legal high’ mephedrone, Bioorg Med Chem Lett, 20, 4135, 10.1016/j.bmcl.2010.05.065

Griffiths, 2010, Khat use and monitoring drug use in Europe: the current situation and issues for the future, J Ethnopharmacol, 132, 578, 10.1016/j.jep.2010.04.046

Hadlock, 2011, 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse, J Pharmacol Exp Ther, 339, 530, 10.1124/jpet.111.184119

Jatav, 2008, CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones, Eur J Med Chem, 43, 1945, 10.1016/j.ejmech.2007.12.003

Kalix, 1992, Cathinone, a natural amphetamine, Pharmacol Toxicol, 70, 77, 10.1111/j.1600-0773.1992.tb00434.x

Kalix, 1985, Pharmacological aspects of the chewing of khat leaves, Pharmacol Rev, 37, 149

Karila, 2010, GHB and synthetic cathinones: clinical effects and potential consequences, Drug Test Anal, 3, 552, 10.1002/dta.210

Kehr, 2011, Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats, Br J Pharmacol, 164, 1949, 10.1111/j.1476-5381.2011.01499.x

Martinez-Clemente, 2012, Interaction of mephedrone with dopamine and serotonin targets in rats, Eur Neuropsychopharmacol, 22, 231, 10.1016/j.euroneuro.2011.07.009

Matecka, 1996, Development of novel, potent, and selective dopamine reuptake inhibitors through alteration of the piperazine ring of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909), J Med Chem, 39, 4704, 10.1021/jm960305h

Meltzer, 2006, 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors, J Med Chem, 49, 1420, 10.1021/jm050797a

Motbey, 2011, Mephedrone (4-methylmethcathinone, ‘meow’): acute behavioural effects and distribution of Fos expression in adolescent rats, Addict Biol

Nagai, 2007, The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain, Eur J Pharmacol, 559, 132, 10.1016/j.ejphar.2006.11.075

National Research Council, 2003

Pehek, 1990, Effects of cathinone and amphetamine on the neurochemistry of dopamine in vivo, Neuropharmacology, 29, 1171, 10.1016/0028-3908(90)90041-O

Proctor, 2007, Regulation of salivary gland function by autonomic nerves, Auton Neurosci, 133, 3, 10.1016/j.autneu.2006.10.006

Psychonaut Research Web Mapping Project, MDPV report, London, UK: Institute of Psychiatry, King's College London; 2009.

Rothman, 2001, Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin, Synapse, 39, 32, 10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3

Saini, 2005, Etiology of xerostomia and dental caries among methamphetamine abusers, Oral Health Prev Dent, 3, 189

Schifano, 2011, Mephedrone (4-methylmethcathinone; ‘meow meow’): chemical, pharmacological and clinical issues, Psychopharmacology, 214, 593, 10.1007/s00213-010-2070-x

Spanagel, 1999, The dopamine hypothesis of reward: past and current status, Trends Neurosci, 22, 521, 10.1016/S0166-2236(99)01447-2

Spanos, 1989, Acute and subchronic effects of methylenedioxymethamphetamine [(+/−)MDMA] on locomotion and serotonin syndrome behavior in the rat, Pharmacol Biochem Behav, 32, 835, 10.1016/0091-3057(89)90044-0

Spiller, 2011, Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States, Clin Toxicol, 49, 499, 10.3109/15563650.2011.590812

Steinpreis, 1999, The effects of atypical antipsychotics and phencyclidine (PCP) on rotorod performance, Pharmacol Biochem Behav, 63, 387, 10.1016/S0091-3057(99)00010-6

Striebel, 2011, Acute psychotic sequelae of “bath salts”, Schizophr Res, 113, 259, 10.1016/j.schres.2011.09.001

Sulzer, 2005, Mechanisms of neurotransmitter release by amphetamines: a review, Prog Neurobiol, 75, 406, 10.1016/j.pneurobio.2005.04.003

Thomas, 2004, Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation, J Pharmacol Exp Ther, 311, 1, 10.1124/jpet.104.070961

U.S. Environmental Protection Agency (U.S. EPA). Guidelines for neurotoxicity risk assessment. Risk assessment forum. Washington, DC: U.S. EPA, 630/R-95/001F; 1998a. Available from: http://www.epa.gov/raf/publications/guidelines-neurotoxicity-risk-assessment.htm.

U.S. Environmental Protection Agency (U.S. EPA). Health effects guidelines: neurotoxicity screening battery. Washington, DC: U.S. EPA, EPA 712-C-98-238. OPPTS 870.6200; 1998b. Available from: http://www.epa.gov/ocspp/pubs/frs/publications/Test_Guidelines/series870.htm.

Walsh, 1992, Motor impairments after methamphetamine-induced neurotoxicity in the rat, J Pharmacol Exp Ther, 263, 617

Winstock, 2010, What should be done about mephedrone?, BJM, 340, c1605, 10.1136/bmj.c1605

Winstock, 2011, Mephedrone, new kid for the chop?, Addiction, 106, 154, 10.1111/j.1360-0443.2010.03130.x

Wise, 1987, A psychomotor stimulant theory of addiction, Psychol Rev, 94, 469, 10.1037/0033-295X.94.4.469

Wohlfarth, 2010, Bioanalysis of new designer drugs, Bioanalysis, 2, 965, 10.4155/bio.10.32

Zelger, 1980, Behavioural effects of cathinone, an amine obtained from Catha edulis Forsk.: comparisons with amphetamine, norpseudoephedrine, apomorphine and nomifensine, Bull Narc, 32, 67